This week: A recent FDA update revealed that nearly 30% of required clinical trial results are missing from public databases. While that may sound like a research issue, it has real implications for employers, healthcare costs, and the advice brokers give every day.
What’s Actually Happening
The FDA recently reminded more than 2,200 companies and researchers that they are required to report clinical trial results. An internal review found that nearly 30% of studies that should have reported results had not done so.
This isn’t just about delayed paperwork. In many cases, the missing data includes studies that were inconclusive or showed a lack of effectiveness. When those results go unreported, the overall picture of how a drug performs becomes incomplete.
According to the FDA, this kind of gap can affect everything from scientific research to real-world treatment decisions.
Why Missing Data Matters
When only positive results are consistently reported, it creates what’s known as publication bias. In simple terms, the successes are visible, and the failures are harder to see.
That can make certain treatments appear more effective than they actually are. It can also influence how future studies are designed, since researchers are often building on existing data that may not tell the full story.
In clinical settings, this matters even more. Physicians and patients are making decisions based on available evidence. If that evidence is incomplete, those decisions may not fully reflect reality.
What This Means for Employers and Health Plans
At first glance, this might seem like an issue limited to researchers and pharmaceutical companies. But the effects show up much further downstream.
Employers are paying for treatments through their health plans. Those costs are often tied to the perceived effectiveness of drugs and therapies. If the underlying data is incomplete, there’s a risk that some treatments are being valued—or priced—based on an overly optimistic view.
Over time, that can contribute to higher costs without a corresponding improvement in outcomes.
This is one of the reasons why healthcare spending can feel disconnected from results. It’s not always intentional, but it is a byproduct of how information flows through the system.
Why Brokers Should Pay Attention
As a broker, you’re not running clinical trials or approving drugs, but you are helping clients make decisions in a system shaped by this data.
When a new treatment is introduced or heavily marketed, it’s easy to assume the full picture is available. Situations like this are a reminder that the information behind those decisions may not always be complete.
That doesn’t mean every treatment is flawed or overpriced. It simply means there are limits to what the data can tell us, and those limits should be acknowledged when advising clients.
Your role is not to challenge the science, but to help clients navigate cost, risk, and value within an imperfect system.
Practical Takeaways
There are a few simple ways to apply this insight in your day-to-day work.
First, be cautious about assuming that newer or more expensive treatments always represent better outcomes. Cost and effectiveness do not always move together.
Second, continue to focus on plan strategies that emphasize value and oversight, such as formulary management, PBM strategy, and alternative funding approaches.
Finally, recognize that part of your role is helping clients make decisions in the face of uncertainty. The goal isn’t perfect information. It’s better decisions with the information available.
Final Thought
Healthcare decisions are only as strong as the information behind them. When parts of that information are missing, even well-intentioned systems can produce imperfect outcomes.
For brokers and employers, this is a reminder of the importance of asking questions, focusing on value, and staying aware of how the system works behind the scenes.
Because in many cases, the biggest risks aren’t obvious—they’re hidden in the gaps.